Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 Operating Income

The latest operating income for CYCCP is $-2.7M as of June 2026. That compares with $-1.8M in the prior-year period — down 46.2% year over year. Investors often review this figure alongside Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's historical trend and sector peers before judging valuation or financial health.

Over the past year, CYCCP's operating income moved from $-1.8M to $-2.7M — a 46.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's operating scale or balance-sheet position.

A operating income figure of $-2.7M for CYCCP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CYCCP's operating income ($-2.7M), review year-over-year change from $-1.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.